Trial of 5-Minute Subcutaneous Rituximab Injection: Positive Results   (7 votes) ProHealth.com • December 10, 2012 Tweet previous article next article Dec 8: Basil, Switzerland-based Roche pharmaceuticals company reports positive results from two international phase III trials of its MabThera – a form of rituximab that can be injected under the skin rather than delivered intravenously. Rituximab is used to treat illnesses involving overactive or dysfunctional immune B cells, such as lymphomas, and some autoimmune disorders such as RA; and, according to pilot trials may benefit at least a subset of ME/CFS patients. (For background click here.) The MabThera studies suggest this subcutaneously delivered rituximab, submitted for approval to the European Medicines Agency on Dec 4: • Requires much less patient time in an infusion center (5 minutes vs. 2-1/2 hours for administration) • Delivers comparable (“noninferior”) concentrations in the blood vs the IV mode of administration, with similar, mostly mild to moderate adverse event and administration related reactions. • Based on an exploratory switch from IV to subcutaneous administration, does not appear to compromise proven response rates (in this case anti-lymphoma efficacy). • And as a ready-to-use formulation should reduce pharmacy and staff preparation and administration time. Source: Based on Roche press release, Dec 8, 2012. For full details, go to http://www.roche.com/med-cor-2012-12-08b.htm

previous article   Rating 5 (7 votes) next article Tweet

RELATED PRODUCT CATEGORIES

ProHealth offers a wide range of nutritional supplements for optimal health.* *These products are not intended to diagnose, treat, cure, or prevent any disease. ME/CFS Support Vitamins

DISCUSS THIS ARTICLE   (0 existing comments)
[ Be the first to comment on this article ]